US Stock Swing: Moderna surged on October 19 driven by cancer vaccine progress, Bank of America raising target price, and mRNA drugs

Moderna's Surge on October 19 Explained

Keywords: Cancer vaccine progress, Bank of America raises target price, mRNA drugs

1. On October 17, results from the phase III study of intismeran autogene, a personalized cancer treatment jointly developed by Moderna and Merck, in combination with Keytruda for melanoma, were presented. Related reports indicated that this candidate therapy has made positive progress.

2. On October 19, Bank of America Global Research raised Moderna’s target price from $200 to $220. The company develops vaccines and therapies based on mRNA technology, with business covering infectious diseases, oncology, and rare diseases.

(Disclaimer: This content is generated by AI technology based on public information and is for reference only. It does not constitute investment advice.)